Menu Search
Equities

Cantourage Group SE

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HIGHX:GER

Cantourage Group SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)4.31
  • Today's Change-0.08 / -1.82%
  • Shares traded19.89k
  • 1 Year change-8.69%
  • Beta--
Data delayed at least 15 minutes, as of Feb 17 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cantourage Group SE is a Germany-based company. The Company is engaged in the production and distribution of medical cannabis. It is engaged in market segments as: dried flowers, extracts, Dronabinol and pharma-grade Cannabidiol, through Cantourage GmbH and its subsidiaries. Cantourage GmbH, one of the subsidiaries, is engaged in the production and wholesale trade of cannabis-based medicinal preparations, as well as the trade of other cannabis products.

  • Revenue in EUR (TTM)2.12m
  • Net income in EUR-95.53k
  • Incorporated2022
  • Employees7.00
  • Location
    Cantourage Group SEFeurigstrasse 54BERLIN 10827GermanyDEU
  • Phone+49 30 470135050
  • Fax+49 30 470135055
  • Websitehttps://www.cantourage.com/
More ▼

Institutional shareholders

0.66%Per cent of shares held by top holders
HolderShares% Held
HANSAINVEST Hanseatische Investment-GmbHas of 31 Dec 202546.70k0.38%
Axxion SA (Luxembourg)as of 30 Jan 202635.37k0.28%
Data from 31 Dec 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.